The product is very well documented with 4 clinical trials in which more than 650 adults and children were included. It has shown good results for the treatment of viral respiratory infections like common cold and flu-like illnesses. The product may be launched already during the first half of 2018, under the name Viruseptin®.
The agreement is long term (10 years).
In the light of this new partnership, Dr. Andreas Grassauer, CEO of Marinomed, said: „Sweden, Norway and Finland are key pharmaceuticals markets. Licensing our product portfolio here at one stroke is an important contribution towards our rapidly growing sales and distribution network.“
„We have planned to enter the market for the treatment of cold and flu symptoms since some time. This product enables us to do so in a competitive way. In parallel we will continue to develop T268A as it will further strengthen our product portfolio given its different mode of action” says Anders Lönner Chairman of the Board, Karo Pharma AB.
In addition to the expansion of its numerous international sales channels, Marinomed is also working intensively on the development of new products on the basis of the MARINOSOLV® technology platform. The company is currently well advanced on the development of a product for allergic rhinitis patients.
ABOUT KARO PHARMA
Karo Pharma is a specialty pharma company that develops and markets products to pharmacies and directly to healthcare providers. The share is listed on Nasdaq Stockholm in the Mid Cap segment.
Dr. Eva Prieschl-Grassauer
Chief Scientific Officer
Tel: +43 (0)1 250 77 - 4460
PR&D – Public Relations für Forschung & Bildung
Tel: +43 (0) 1 505 70 44